In short
NALIRIFOX is a chemotherapy treatment used for pancreatic cancer [1]. It combines four medicines: liposomal irinotecan, fluorouracil, leucovorin, and oxaliplatin [2]. It is used for advanced cancer that has spread to other parts of the body [1].
The details
NALIRIFOX is given as an intravenous infusion over 46 hours on days 1 and 15 of a 28-day cycle [1].
In patients with metastatic pancreatic ductal adenocarcinoma, NALIRIFOX helped people live longer than the combination of gemcitabine and nab-paclitaxel [1].
The median overall survival was 11.1 months for those taking NALIRIFOX compared to 9.2 months for those taking gemcitabine and nab-paclitaxel [1].
NALIRIFOX is also being studied as a treatment before surgery for patients with resectable or borderline resectable pancreatic cancer [4].
In this setting, it helped shrink the tumor in 45% of patients and allowed most patients to complete all planned cycles of treatment [4].
What to know
NALIRIFOX is generally used for advanced or metastatic disease as a first-line treatment [1].
It can cause side effects. In trials, high-grade adverse events occurred in about 87% of patients taking NALIRIFOX [1].
Treatment decisions should be made with a doctor who knows your specific health situation [3].
⚕️ This is for learning, not treatment decisions. Always talk with your oncology team — they know your full situation. The information here comes from published research and is meant to help you have better conversations with your doctors.